vimarsana.com

Page 31 - ஹ்ஸீ வேந்‌ரைட் உலகளாவிய வாழ்க்கை அறிவியல் மாநாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sequana Medical announces February-March 2021 Investor Conference Schedule Brussels Stock Exchange:SEQUA

Sequana Medical announces February-March 2021 Investor Conference Schedule

Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update

Press release content from Business Wire. The AP news staff was not involved in its creation. Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update February 12, 2021 GMT LYON, France (BUSINESS WIRE) Feb 12, 2021 POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the twelve months ended December 31, 2020 and provided a corporate update. ADVERTISEMENT “Despite the challenges posed by the COVID-19 pandemic, Poxel ended 2020 on a strong note, having accomplished several important corporate and clinical milestones and positioning the Company for an exciting 2021. We continued working closely with our partner Sumitomo Dainippon Pharma to further advance the review of the Japanese New Drug Application for Imeglimin follo

ORYZON to Present New Clinical Data and Corporate Updates at Conferences in February and March

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ORYZON to Present New Clinical Data and Corporate Updates at Conferences in February and March Oryzon Genomics, S.A.February 10, 2021 GMT 2021 BIO CEO & Investor Digital Conference 15th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD 2021 H.C. Wainwright Global Life Sciences Conference BioCapital Europe 2021 33rd Annual ROTH Conference MADRID, Spain and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that it will present new clinical data and attend several industry conferences in February and March, all in virtual format due to the Covid-19 pandemic.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.